Anti-Human C5 (Eculizumab) (C3040-5mg)

Complement component 5 (C5) is a crucial protein in the complement system, part of the body’s immune response. It is synthesized in the liver and circulates in the blood as an inactive precursor. When triggered, C5 splits into C5a and C5b. C5a acts as an inflammation promoter and attracts immune cells to infection sites. C5b kickstarts the creation of the membrane attack complex (MAC), which creates pores in the membranes of pathogens, leading to their destruction. Irregularities in C5 activation are linked to illnesses such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)1,2. The clone 5G1.1, also known as Eculizumab, is a humanized monoclonal antibody designed to target the complement protein C5. Binding to C5 prevents its cleavage into C5a and C5b, thereby blocking the formation of the membrane attack complex (MAC). This inhibition is essential for reducing the inflammatory and cell-lysing effects that come with complement activation. Eculizumab has received approval for treating paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), both of which are rare, life-threatening conditions resulting from uncontrolled complement activation. Its effectiveness in these disorders has established it as a pioneering treatment in immunology3-9.